

## Interventional Procedures Advisory Committee: Committee Interests Register

**Topic: HTG10870 (IP1062-3) - Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver**

NICE's declaration of interest policy can be accessed [here](#)

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Rick Body	Standing Committee Member (Chair)	Financial	Nil	N/A	10/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	10/03/2026	N/A	No further action
		Indirect	Nil	N/A	10/03/2026	N/A	No further action
Simon Bach	Standing Committee Member (Vice-Chair)	Financial	Nil	N/A	27/05/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	27/05/2026	N/A	No further action
		Indirect	Nil	N/A	27/05/2026	N/A	No further action
Angus McNair		Financial	Nil	N/A	23/03/2026	N/A	No further action

	Standing Committee Member	Non-financial professional and personal	Nil	N/A	23/03/2026	N/A	No further action
		Indirect	Nil	N/A	23/03/2026	N/A	No further action
Augusto Azuara-Blanco	Standing Committee Member	Financial	Nil	N/A	09/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action
		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Christopher Adams	Standing Committee Member	Financial	Nil	N/A	11/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	11/03/2026	N/A	No further action
		Indirect	Nil	N/A	11/03/2026	N/A	No further action
Conrad Harrison	Standing Committee Member	Financial	Nil	N/A	06/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	06/03/2026	N/A	No further action
		Indirect	Nil	N/A	06/03/2026	N/A	No further action
Dawn Lee		Financial	Nil	N/A	09/03/2026	N/A	No further action

	Standing Committee Member	Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action
		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Mahmoud Elfar	Standing Committee Member	Financial	Nil	N/A	25/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	25/03/2026	N/A	No further action
		Indirect	Nil	N/A	25/03/2026	N/A	No further action
Marwan Habiba	Standing Committee Member	Financial	Nil	N/A	06/04/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	06/04/2026	N/A	No further action
		Indirect	Nil	N/A	06/04/2026	N/A	No further action
Noemi Muszbek	Standing Committee Member	Financial	I do not have a conflict of interest in primary or metastatic cancer in the liver, however Visible Analytics, where I am Partner (part-owner) and HE Director provides consultancy services to Aura Biosciences, a project that I am also involved in, in early uveal melanoma.	27/08/2025	16/04/2026	Ongoing	No further action
		Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action

		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Paddy Storrie	Standing Committee Member	Financial	Nil	N/A	09/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action
		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Patrick Farrell	Standing Committee Member	Financial	Nil	N/A	18/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	18/03/2026	N/A	No further action
		Indirect	Nil	N/A	18/03/2026	N/A	No further action
Sandeep Singh Randhawa	Standing Committee Member	Financial	Nil	N/A	17/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	17/03/2026	N/A	No further action
		Indirect	Nil	N/A	17/03/2026	N/A	No further action
Stuart Smith	Standing Committee Member	Financial	Nil	N/A	09/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action

		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Suvitesh Luthra	Standing Committee Member	Financial	Nil	N/A	09/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action
		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Tim Kinnaird	Standing Committee Member	Financial	Nil	N/A	10/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	10/03/2026	N/A	No further action
		Indirect	Nil	N/A	10/03/2026	N/A	No further action
Veena Soni	Standing Committee Member	Financial	Nil	N/A	09/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	09/03/2026	N/A	No further action
		Indirect	Nil	N/A	09/03/2026	N/A	No further action
Joseph Sacco	Professional Expert	Financial	Paid involvement in an educational meeting on PHP (co-chair and speaker). Income £1,250.	Aug-25	19/12/2025	23 March 2026 (further meeting planned)	No further action
		Financial	Delcath advisory board meeting. Received personal income of £1,700	May-18	19/12/2025	May-18	Declare and participate

		Non-financial professional and personal	I recently participated in a Delcath sponsored advisory board with a group of experts in the field in which we sought to come to consensus statements around the use of the PHP in uveal melanoma. This has not been finalized or published; in the event publication I will highlight the publication to the committee.	Nov-25	19/12/2025	Nov-25	Declare and participate
		Indirect	I was local PI for a delcath sponsored trial which was published last year	2017	19/12/2025	2024	Declare and participate
		Indirect	I have attended advisory boards for delcath with payments to institution rather than to self	Nov-25	19/12/2025	Nov-25	Declare and participate
		Indirect	I have also attended advisory boards for other companies with trials or treatments in uveal melanoma space, including Immunocore, BMS, Replimune	~2014	19/12/2025	Ongoing	No further action
		Indirect	I am or have been local PI on a number of clinical trials in uveal melanoma sponsored by other companies (including Immunocore and Replimune in particular)	~2015	19/12/2025	Ongoing	No further action
Matthew Wheater	Professional Expert	Financial	Attendance at ESMO Conference 2025 Support (flights to Berlin and hotel accomodation) from Delcath systems	16/10/2025	15/12/2025	20/10/2025	Declare and participate
		Financial	Consultancy fees Delcath systems - £500	04/11/2025	15/12/2025	04/11/2025	Declare and participate
		Non-financial professional and personal	Senior author UK Occular melanoma guidelines	01/10/2025	15/12/2025	01/10/2025	No further action

		Non-financial professional and personal	PPP (Preliminary policy proposal) lead on CPAG application for melphalan-PHP for liver dominant metastatic uveal melanoma	01/01/2025	15/12/2025	Ongoing	Declare and participate
		Indirect	Nil	N/A	15/12/2025	N/A	No further action
Mona Dave	Professional Expert	Financial	Nil	N/A	10/03/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	10/03/2026	N/A	No further action
		Indirect	Nil	N/A	10/03/2026	N/A	No further action
Sanjay Gupta	Professional Expert	Financial	Private practice: providing anaesthesia and critical care service for private and NHS patients	2012	24/11/2025	Ongoing	No further action
		Financial	International proctor: I provide proctorship and training to new centres principally in Europe and USA. This is reimbursed by the company (Delcath Inc (HQ Ireland))	01/07/2013	24/11/2025	Ongoing	Declare and participate
		Financial	I provide clinical advice at Ad board meetings to direct future progress of the service (approximately £1200 per year or less)	01/07/2013	24/11/2025	Ongoing	Declare and participate
		Non-financial professional and personal	Nil	N/A	24/11/2025	N/A	No further action
		Indirect	Nil	N/A	24/11/2025	N/A	No further action

Stephen Mackworth-Green	Patient Expert	Financial	Nil	N/A	25/02/2026	N/A	No further action
		Non-financial professional and personal	Nil	N/A	25/02/2026	N/A	No further action
		Indirect	Nil	N/A	25/02/2026	N/A	No further action
Jo Gumbs	Patient Expert	Financial	Nil	N/A	23/03/2026	N/A	No further action
		Non-financial professional and personal	Chief Executive of Ocular Melanoma UK, a patient advocacy charity supporting individuals affected by uveal melanoma. The organisation provides patient support services, contributes to policy discussions, and advocates for improved access to treatments. This role includes representing the patient perspective in discussions relevant to ocular melanoma treatments.	October 2009	23/03/2026	Ongoing	Declare and participate
		Non-financial professional and personal	Regular engagement with patients who have undergone treatments including Chemosat, providing insight into lived experience and outcomes which may inform my contributions.	Ongoing	23/03/2026	Ongoing	No further action
		Indirect	Ocular Melanoma UK, the charity I work for, received funding of £20,000 from Delcath Systems  This funding supports activities such as patient conferences and community support initiatives.	July 2025	23/03/2026	Ongoing	Declare and participate

			<p>We also received other grants from pharmaceutical companies and I receive no personal financial benefit. While my role involves representing the patient community, the charity maintains independence in its activities and advocacy, and funding is not linked to specific positions taken in policy or advisory settings.</p>				
		Indirect	<p>Delcath Systems are covering reasonable expenses for my attendance at clinical meetings and will make a payment to Ocular Melanoma UK for my time at two events so that clinicians can hear more about the patient experience.</p> <p>This payment is made at fair market value to the organisation, with no personal financial benefit to me. The charity retains full independence in its activities and advocacy, and this arrangement does not determine the views I present.</p>	September 2025	23/03/2026	March 2026	Declare and participate